Canada clears Cyberonic's VNS (vagus nerve stimulation) therapy for depression:
This article was originally published in Clinica
Executive Summary
Cyberonics has gained the go-ahead in Canada to market its implantable vagus nerve stimulation (VNS) device for the treatment of chronic or recurrent depression. The NeuroCybernetic Prosthesis system, which is indicated for use in patients who are resistant or intolerant, can now be targeted at around 100,000 Canadians who suffer form the condition, says the Houston, Texas company. The product first became available as a treatment for depression in Europe last month (see Clinica No 950, p 17).